WHO Health Systems Library
Change to French interface versionChange to Spanish interface version
Drug Promotion - What We Know, What We Have Yet to Learn - Reviews of Materials in the WHO/HAI Database on Drug Promotion - EDM Research Series No. 032
(102 pages)

Table of Contents
View the documentAcknowledgements
View the documentExecutive summary
close this folderIntroduction
View the documentBackground to the project
View the documentDevelopment of the drug promotion database
View the documentDatabase entries
View the documentPotential data users
View the documentReviews of database material
View the documentMethodology
Open this folder and view contentsReview 1. What attitudes do professional and lay people have to promotion?
Open this folder and view contentsReview 2. What impact does pharmaceutical promotion have on attitudes and knowledge?
Open this folder and view contentsReview 3. What impact does pharmaceutical promotion have on behaviour?
Open this folder and view contentsReview 4. What interventions have been tried to counter promotional activities, and with what results?
View the documentFinal conclusions
View the documentReferences

Background to the project

The impetus for a major project on pharmaceutical promotion originated at the May 1999 meeting of the WHO/Public-Interest Nongovernmental Organizations Roundtable on Pharmaceuticals. Unethical and inappropriate drug promotion has been a continuing concern of both NGOs and the WHO. At the 1997 Roundtable on WHO's Ethical Criteria for Medicinal Drug Promotion there was firm agreement that inappropriate promotion of medicinal drugs remains a problem both in developing and developed countries.

Although there is an abundance of information about drug promotion it had never been fully documented and as such organizations, governments, individuals and others were restricted in their ability to access the breadth of knowledge that had been accumulated, to analyse it, to learn from it and to expand on it. Therefore, the first phase of the promotion project was to collect, analyse and make publicly accessible as wide a range of material as possible that described, analysed, reported or commented on any aspect of pharmaceutical promotion.

This drug promotion project is a collaboration between the WHO Department of Essential Drugs and Medicines Policy (EDM) and Health Action International (HAI) Europe.

to previous section to next section
Last updated: May 4, 2012